293 related articles for article (PubMed ID: 32732367)
1. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
[TBL] [Abstract][Full Text] [Related]
2. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
[TBL] [Abstract][Full Text] [Related]
3. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
[TBL] [Abstract][Full Text] [Related]
4. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
Xu Y; Li W; Gan J; He X; Huang X
Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
[TBL] [Abstract][Full Text] [Related]
5. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
Yan WL; Yang SL; Zhao FY; Xu XJ
J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
Meng G; Wang J; Wang X; Wang Y; Wang Z
Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
[TBL] [Abstract][Full Text] [Related]
9. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
[TBL] [Abstract][Full Text] [Related]
10. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
Sin JH; Zangardi ML
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
[TBL] [Abstract][Full Text] [Related]
13. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
[No Abstract] [Full Text] [Related]
14. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report.
Zhu M; Zhang J; Shi Q; Sun X; Wang H; Sun M; Liu Y
Iran J Immunol; 2023 Dec; 20(4):466-472. PubMed ID: 37873944
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
Huang Z; Xie J
Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
[TBL] [Abstract][Full Text] [Related]
16. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection.
Gálvez Acosta S; Javalera Rincón M
Int J Hematol; 2020 Sep; 112(3):418-421. PubMed ID: 32285358
[TBL] [Abstract][Full Text] [Related]
20. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
Song Y; Wang J; Wang Y; Wang Z
Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
